Comparison of 5-azacytidine (NSC-102816) with CCNU (NSC-79037) in the treatment of patients with breast cancer and evaluation of the subsequent use of cyclophosphamide (NSC-26271).
D000284:Administration, Oral; D000970:Antineoplastic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D001374:Azacitidine / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D001943:Breast Neoplasms / Q000188:drug therapy* / Q000276:immunology; D002713:Chlorine / Q000276:immunology; D003510:Cyclohexanes / Q000008:administration & dosage / Q000009:adverse effects / Q000031:analogs & derivatives / Q000627:therapeutic use; D003520:Cyclophosphamide / Q000008:administration & dosage / Q000627:therapeutic use*; D004305:Dose-Response Relationship, Drug; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D007275:Injections, Intravenous; D008593:Menopause; D009362:Neoplasm Metastasis; D009578:Nitrobenzenes / Q000276:immunology; D009607:Nitrosourea Compounds / Q000008:administration & dosage / Q000009:adverse effects / Q000627:therapeutic use*; D012075:Remission, Spontaneous; D012882:Skin Tests
D000970:Antineoplastic Agents; D003510:Cyclohexanes; D009578:Nitrobenzenes; D009607:Nitrosourea Compounds; D002713:Chlorine; D003520:Cyclophosphamide; D001374:Azacitidine